Search results
www.beximco.com
- Non-Current Assets
- Current Assets
- Equity Attributable to the Owners of the Company
- Non-Current Liabilities
- Current Liabilities and Provisions
- A B Siddiqur Rahman Nazmul Hassan Mohammad Ali Nawaz
- Operating Expenses
- Profit/(Loss) Attributable to:
- Mohammad Asad Ullah, FCS
- A B Siddiqur Rahman Nazmul Hassan Mohammad Ali Nawaz
- 1.3 Nature of Business
- 4.2 Inter-Company Transactions
- 4.3. Non-Controlling Interests (NCIs)
- 4.4. Valuation of Goodwill
- 5. Property, Plant & Equipment - Carrying Value
- 7. Other Investments
- 8. Inventories
- A. Net of Current Maturity
- B. Current Maturity
- 12. Cost of Goods Sold
- Cost of Goods Manufactured
- Finished Goods available
- 4,392,976 13. Administrative Expenses For the Period July - September 2022
- 14. Selling, Marketing and Distribution Expenses
- i. Beximco Pharma
- Temporary Difference
- Change in Deferred Tax Liability
- ii. Nuvista Pharma
- Temporary Difference
- iii.Synovia Pharma
- A B Siddiqur Rahman Nazmul Hassan Mohammad Ali Nawaz
- Non-Current Assets
- Current Assets
- Shareholders' Equity
- Non-Current Liabilities
- Current Liabilities and Provisions
- A B Siddiqur Rahman Nazmul Hassan Mohammad Ali Nawaz
- Operating Expenses
- Profit Before Contribution to WPPF & Welfare Funds
- A B Siddiqur Rahman Nazmul Hassan Mohammad Ali Nawaz
- Cash Flows from Operating Activities :
- Cash Generated from Operations
- Cash Flows from Investing Activities :
- Cash Flows from Financing Activities :
- Net Cash (Used in ) / from Financing Activities Increase/(Decrease) in Cash and Cash Equivalents
- Cash and Cash Equivalents at End of Period
- 1.2 Nature of Business
- 3. Property, Plant & Equipment - Carrying Value
- 4b. Other Investment
- 5. Inventories
- A. Net of Current Maturity
- B. Current Maturity
- 10. Cost of Goods Sold
- 11. Administrative Expenses
- 12. Selling, Marketing and Distribution Expenses
- 13. Other Income
- 14. Deferred Tax
- Temporary Difference
- Profit after Tax
- Non-cash / Non-operating Items:
Property, Plant and Equipment- Carrying Value Right-of-use Assets Intangible Assets Deferred Tax Asset Goodwill Other Investments
Inventories Spares & Supplies Accounts Receivable Loans, Advances and Deposits Advance Income Tax Cash and Cash Equivalents TOTAL ASSETS
Issued Share Capital Share Premium Excess of Issue Price over Face Value of GDRs Capital Reserve on Merger Revaluation Surplus Unrealized Gain/(Loss) Retained Earnings Non-Controlling Interests
Long Term Borrowings-Net of Current Maturity Liability for Gratuity, Pension and WPPF & Welfare Funds Deferred Tax Liability
Short Term Borrowings Long Term Borrowings-Current Maturity Creditors and Other Payables Accrued Expenses Dividend Payable / Unclaimed Dividend Income Tax Payable
Director Managing Director Chief Financial Officer
Administrative Expenses Selling, Marketing and Distribution Expenses
Owners of the Company Non-controlling Interest Other Comprehensive Income/(Loss) Total Comprehensive Income
Executive Director & Company Secretary Beximco Pharmaceuticals Limited and its Subsidiaries
Director Managing Director Chief Financial Officer
BPL is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a wide range of therapeutic categories. It offers products in different dosage forms including Solid, Liquid, Cream and Ointment, Suppositories, Metered Dose Inhaler, Dry Powder Inhaler, Nasal Spray, Sterile, Lyophilized Injectable and Large Volum...
Assets, Liabilities, Equity, Income, Expenses and Cash Flows arising out of transactions between the Company and the subsidiaries have been eliminated in full in the Consolidated Financial Statements.
Non-Controlling Interests (NCIs) at the date of acquisition has been measured at fair value of the net assets of the acquired company in proportion to the shares of the entitled holders. Profit or Loss and Other Comprehensive Income subsequent to the acquisition has been allocated to the Owners of the Company and to the NCIs.
Goodwill has been determined in accordance with IFRS 3: Business Combination. This represents the excess of the aggregate of Purchase Consideration and the acquisition-date fair value of NCI’s share in the net assets over the acquisition-date fair value of the net assets of the subsidiary.
Land Building and Other Constructions Plant and Machinery Furniture and Fixtures Transport and Vehicle Office Equipment Less :Accumulated Depreciation
Bangladesh Export Import Co. Ltd. Central Depository Bangladesh Ltd. (CDBL)
Finished Goods Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit) Physician Sample
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany Term Loan- Agrani Bank Term Loan- Dhaka Bank Lease Liability
Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany Term Loan- Agrani Bank Term Loan- Dhaka Bank Lease Liability
Work-in-Process (Opening) Materials Consumed Factory Overhead Consumed
Finished Goods (Opening) Purchase (Imported and processed)
Cost of Sample (transferred to Sample Stock) Finished Goods (Closing)
Salary & Allowances Repairs & Maintenance Travelling & Conveyance Company Secretarial, Regulatory Fee and AGM Expense Depreciation Security Expenses Business Acquisition Cost Other Expenses
Salary & Allowances Travelling & Conveyance Market Research & New Products Sample Expenses Literature and News Letter Events, Programs & Campaigns Brand Development Sales Promotion Expenses Distribution Commission Delivery Expense Depreciation and Amortization Export Insurance, Freight and C & F Expenses Security Expenses Bad Debts Other Expenses
Property, Plant & Equipment ( Difference in book value & Tax base) Deferred liability (Gratuity) Provision for Bad Debts
Tax Rate Deferred Tax Liability at end of the period Deferred Tax Liability at beginning of the period
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Depreciation Amortization Deferred Tax Exchange Rate Fluctuation Loss on Foreign Currency Bank Loan Loss /(Gain)on Sale of Fixed Assets Effect of Exchange Rate Changes on Cash and Cash Equivalents
Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. BPL is the largest exporter of generic drugs in the country and its state-of-the-art manufacturing facilities are already certified by major global regulatory authorities like TGA, GCC and ANVISA, while awaiting audits and approvals by US FDA ...
prepared audited financial statements for the six month ending June 30, 2022 to align its accounting year with that of the parent company. We have audited the Financial statements of Beximco Pharma API Limited and expressed our unmodified opinion on those statements vide our report dated October 27, 2022.
BEXIMCO - Taking Bangladesh to the World
The Accounting year of the subsidiary companies- Beximco Pharma API Limited, Nuvista Pharma Limited and Synovia Pharma PLC, ends on the same date as of the Company. We have audited the Financial statements of Beximco Pharma API Limited and expressed our unmodified opinion on those statements vide our report dated October 19, 2023.
People also ask
Which subsidiaries have been consolidated with Beximco Pharmaceuticals Limited?
When does the accounting year of Beximco Pharma API & NuVista Pharma plc end?
Who is Beximco Pharmaceuticals Limited?
Who is Beximco Pharmaceuticals Limited (BPL)?
What is Beximco Pharma's share of accumulated loss of Biocare?
Is Beximco Pharma a subsidiary of NuVista Pharma Ltd?
Nov 8, 2022 · Beximco Pharmaceuticals Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported sales was BDT 34,669.17 million compared to BDT 29,493.57 million a year ago. Net income was BDT 5,123.14 million compared to BDT 5,127.69 million a year ago.
